ArticlePrecision radiation oncology2025
Comparing simultaneous integrated boost whole-brain radiotherapy and local irradiation for brain metastases in lung cancer: A retrospective analysis.
Article in Precision radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparing simultaneous integrated boost whole-brain radiotherapy and local irradiation for brain metastases in lung cancer: A retrospective analysis.Precision radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the differences between simultaneous integrated boost whole-brain radiotherapy (SIB-WBRT) and brain metastases local irradiation efficacy, and determine predictors of outcomes for lung cancer brain metastases patients in therapy. Methods: This retrospective analysis evaluated patients with brain metastases treated with SIB-WBRT (whole brain at 40 Gy/20 fractions, tumor boosted to 56-60 Gy/20 fractions) and localized irradiation (prescribed doses ranging from 20-60 Gy over 2-25 fractions, typically administered as 30 Gy/5 fractions, with a biologically effective dose [BED] of 28-100.8 Gy) at PUMCH between September 2015 and December 2021. The primary outcome was intracranial progression-free survival (iPFS), with secondary outcomes encompassing overall survival (OS), development of new intracranial lesions, and tumor control. Propensity score matching was employed to compare the two retrospective groups. Survival curves for iPFS, OS, new intracranial lesions, and tumor control were generated and estimated using the Kaplan-Meier approach. Cox proportional hazards modeling was applied to examine the relationships between pertinent variables and clinical outcomes. Results: After Propensity score matching, 59 patients were enrolled in each group (SIB-WBRT and local irradiation), with a total of 118 patients included in the analysis. No significant difference was observed between the 2 groups in iPFS (HR = 0.8, 95%CI: 0.4-1.3, Conclusion: Compared to local irradiation, SIB-WBRT did not significantly improve iPFS in patients with brain metastases. Compared to SIB-WBRT, local irradiation improved local control. Tumor volume and other factors may be associated with local control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.